CNS Pharmaceuticals (CNSP) Retained Earnings (2018 - 2025)
CNS Pharmaceuticals' (CNSP) quarterly Retained Earnings came in at -$100.3 million in Q4 2025, down 210.68% YoY from $90.6 million in Q4 2024, and down 196.21% on a QoQ basis from $104.2 million in Q3 2025.
CNS Pharmaceuticals (CNSP) Retained Earnings (2018 - 2025) Analysis & Trends
CNS Pharmaceuticals (CNSP) has 8 years of Retained Earnings data on file, last reported at -$100.3 million in Q4 2025.
- Quarterly Retained Earnings fell 210.68% year-over-year to -$100.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$100.3 million (down 210.68% YoY) and the FY2025 annual result came in at -$100.3 million, down 210.68% from the prior year.
- Retained Earnings slipped to -$100.3 million in Q4 2025, from $104.2 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $104.2 million in Q3 2025 to a low of -$100.3 million in Q4 2025.
- A 5-year average of -$15.2 million and a median of -$40.0 million in 2022 frame the typical range for Retained Earnings.
- The widest YoY moves for Retained Earnings: up 365.87% in 2021, down 257.79% in 2021.
- Tracing CNSP's Retained Earnings over 5 years: stood at -$35.4 million in 2021, then jumped by 266.04% to $58.8 million in 2022, then plunged by 218.22% to -$69.6 million in 2023, then soared by 230.24% to $90.6 million in 2024, then slumped by 210.68% to -$100.3 million in 2025.
- The last three Retained Earnings figures came in at -$100.3 million (Q4 2025), $104.2 million (Q3 2025), and $104.2 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -6.33 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.57 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 4.38 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 20.91 Bn |
| 10 | CNS Pharmaceuticals | 2.66 Mn | -4.54 Mn | - | 104.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -100.28 Mn |
| Sep 30, 2025 | 104.23 Mn |
| Jun 30, 2025 | 104.23 Mn |
| Mar 31, 2025 | -88.73 Mn |
| Dec 31, 2024 | 90.60 Mn |
| Sep 30, 2024 | -81.25 Mn |
| Jun 30, 2024 | -75.64 Mn |
| Mar 31, 2024 | -73.11 Mn |
| Dec 31, 2023 | -69.57 Mn |
| Sep 30, 2023 | -64.19 Mn |
| Jun 30, 2023 | 62.12 Mn |
| Mar 31, 2023 | -55.65 Mn |
| Dec 31, 2022 | 58.85 Mn |
| Sep 30, 2022 | -44.75 Mn |
| Jun 30, 2022 | -42.16 Mn |
| Mar 31, 2022 | -37.77 Mn |
| Dec 31, 2021 | -35.44 Mn |
| Sep 30, 2021 | -32.19 Mn |
| Jun 30, 2021 | 40.75 Mn |
| Mar 31, 2021 | 35.78 Mn |